News
Stories by SWNS on MSN5h
"My work stress headache was actually rare brain disease which left me paralysed"A 'fit and healthy' woman was left paralysed after headaches she thought were 'work stress' turned out to be signs of an ...
Precision BioSciences Inc., a clinical-stage company developing gene editing therapies for diseases with high unmet need, has ...
The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...
From symptoms to the illness' risk factors — here’s what you need to know about the disease, which can only be detected by ...
The accountant began suffering from severe headaches during her 20s until she was diagnosed with brain arteriovenous ...
Parents David and Karen Kahn took their twins to the doctor right before their 7th birthday. During the visit, their ...
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...
The survey primarily focused on rare disease patients between the ages of 16 and 23, as well as caregivers between 25 to 55 years old. Hemophilia, albinism, cystic fibrosis and Gaucher disease were ...
Biogen’s Qalsody (tofersen) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first ...
CHAPEL HILL, N.C. (WTVD) -- A father and mother in Chapel Hill are sharing their painful family story to raise awareness ...
(Reuters) -Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as ...
Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results